Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,223 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $9.32, for a total transaction of $207,118.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Adrian Haigh also recently made the following trade(s):

• On Friday, April 19th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.34, for a total value of $207,553.48.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total value of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total value of $228,886.60.

Fennec Pharmaceuticals Trading Down 1.5 %

FENC stock opened at $9.24 on Wednesday. The firm has a market cap of $250.40 million, a P/E ratio of -15.15 and a beta of 0.38. The stock’s 50 day simple moving average is $10.05 and its 200 day simple moving average is $9.42. Fennec Pharmaceuticals Inc has a 12-month low of $6.30 and a 12-month high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. On average, research analysts forecast that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Fennec Pharmaceuticals

Several institutional investors have recently made changes to their positions in FENC. Tower Research Capital LLC TRC lifted its holdings in shares of Fennec Pharmaceuticals by 107.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock worth $34,000 after purchasing an additional 1,578 shares during the last quarter. Hartford Financial Management Inc. boosted its holdings in shares of Fennec Pharmaceuticals by 4.4% during the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after acquiring an additional 2,000 shares during the period. Gendell Jeffrey L grew its position in shares of Fennec Pharmaceuticals by 0.9% during the third quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after acquiring an additional 2,579 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Fennec Pharmaceuticals in the 3rd quarter worth about $50,000. Finally, Jump Financial LLC acquired a new stake in shares of Fennec Pharmaceuticals in the fourth quarter valued at approximately $158,000. 55.51% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Wedbush restated an “outperform” rating and issued a $16.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th. Craig Hallum upped their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, HC Wainwright lifted their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Thursday, April 4th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.